Clinical trial
Combination Chemotherapy in Treating Patients With Bladder Cancer
NCT00003701 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00003701 |
|---|---|
| Title | Combination Chemotherapy in Treating Patients With Bladder Cancer |
| Official title | A Phase III Randomized Trial of Either M-VAC or Paclitaxel + Carboplatin as Postoperative Adjuvant Therapy in Patients With Muscle-Invasive Transitional Cell Carcinoma of the Bladder at High-Risk for Relapse |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Bladder Cancer, Urethral Cancer |
| Intervention type | Drug |
| Interventions | carboplatin, cisplatin, doxorubicin hydrochloride, methotrexate, paclitaxel, vinblastine sulfate |
| Enrollment | 490 |
| Start date | Apr 2, 1999 |
| Primary completion | Aug 1, 2001 |
| Completion | Jun 15, 2007 |
| First posted | Apr 23, 2004 |
| Last update posted | Jun 15, 2023 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: